Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency

Last updated: March 6, 2025
Sponsor: Seattle Institute for Biomedical and Clinical Research
Overall Status: Active - Recruiting

Phase

2

Condition

Pain (Pediatric)

Cancer

Hypogonadism

Treatment

testosterone 1.62% gel

placebo gel

Clinical Study ID

NCT04301765
AG061558
  • Ages > 55
  • Male

Study Summary

This is a large randomized, double-blind, placebo-controlled trial to determine the efficacy of testosterone replacement on cancer-related fatigue in older men with solid or hematologic (blood) cancer who report fatigue and have low testosterone levels.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men with active solid or hematologic (blood) cancers who have received or arereceiving chemo- and/or radiation therapy. Patients who have no evidence of disease (NED) for 60 months or less, which means that they are <60 months from their lasttreatment (chemotherapy and/or radiation therapy) will be included.

  • Age: 55 years and older

  • Life expectancy of at least 6 months.

  • Serum testosterone, measured by mass spectrometry (gold standard method), of <348ng/dl and/or free testosterone <70 pg/ml. The lower limits of the normal range fortotal testosterone in healthy men is 348 ng/dL and the lower limits of freetestosterone is <70 pg/ml in the Framingham Heart Study sample. As sex hormonebinding globulin levels may be elevated in some men with cancer (resulting inelevation in total testosterone level), some of these symptomatic men may still behypogonadal despite having total testosterone above this cut-off limit, but theirfree testosterone levels may still be below the lower limit of normal. Thus, menwith free testosterone <70 pg/mL will be included.

  • Fatigue. Fatigue was selected as it is a highly prevalent symptom in cancerpatients. Fatigue will be defined as a score on FACIT-Fatigue subscale of <40, whichbest divides cancer patients from the general population with accuracy.

  • Ability and willingness to provide informed consent

Exclusion

Exclusion Criteria:

  • Men with current or prior history of prostate, breast, testicular, or adrenalcancers.

  • Use of anabolic agents (testosterone, DHEA, growth hormone) within the past 6 months

  • Hematocrit >48%, serum creatinine >2.5 mg/dL

  • PSA >4 ng/ml; nodule or induration on digital rectal exam

  • Severe untreated sleep apnea

  • Uncontrolled congestive heart failure

  • Myocardial infarction, acute coronary syndrome, revascularization surgery, stroke orthromboembolism (of any etiology) within 6 months

  • Known history of thrombophilia due to a genetic mutation (e.g. Factor V Leiden)

  • Previous stroke with residual cognitive or functional deficits

  • Inability to provide informed consent; MMSE score <24

  • Poorly controlled diabetes as defined by hemoglobin A1c >10.0%

  • Body mass index (BMI) >40 kg/m2

  • Bipolar disorder or schizophrenia

Study Design

Total Participants: 230
Treatment Group(s): 2
Primary Treatment: testosterone 1.62% gel
Phase: 2
Study Start date:
January 12, 2021
Estimated Completion Date:
January 31, 2026

Study Description

The overall objective is to conduct a double-blind, randomized, placebo-controlled, parallel group trial to determine the efficacy of 6 months of physiological testosterone replacement therapy in improving cancer related fatigue, sexual dysfunction, and body composition and muscle function in men 55 years and older with solid or hematologic (blood) cancers, who report fatigue and have testosterone deficiency. There will be 5 study visits: 1) Screening, 2) Baseline, 3) 2-Week Dose Adjustment Visit, 4) Three-month visit (Week 12), and 5) Six-month visit. Testosterone or placebo gels will be applied by eligible trial participants at home; participants will be trained on gel application procedures by research personnel.

Connect with a study center

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia 30912
    United States

    Active - Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

  • The Massey Cancer Center at Virginia Commonwealth University

    Richmond, Virginia 23298
    United States

    Site Not Available

  • Veterans Affairs Puget Sound Health Care System

    Seattle, Washington 98108
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.